Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multiple sclerosis and amyotrophic lateral sclerosis; VRN13 to treat pulmonary arterial hypertension; and VRN14 for the treatment of refractory solid cancer. Voronoi, Inc. was founded in 2015 and is based in Incheon, South Korea.
Metrics to compare | 310210 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship310210PeersSector | |
|---|---|---|---|---|
P/E Ratio | −76.9x | −14.6x | −0.6x | |
PEG Ratio | 4.65 | −0.33 | 0.00 | |
Price/Book | 68.3x | 6.0x | 2.6x | |
Price / LTM Sales | 485.2x | 33.7x | 3.3x | |
Upside (Analyst Target) | 33.0% | 25.1% | 42.7% | |
Fair Value Upside | Unlock | −3.0% | 4.7% | Unlock |